Idera reports FDA hold lifted on dual TLR7/TLR9 antagonist study
This article was originally published in Scrip
Executive Summary
A day after Idera Pharmaceuticals' shares soared as high as 24.6% after German drug maker Merck KGaA returned the global rights to IMO-2055, a toll-like receptor 9 (TLR9) agonist under investigation to treat various cancers, the Cambridge, Massachusetts-based biotech said the US FDA lifted the hold on the company's Phase II trial for its dual TLR7/TLR9 antagonist IMO-3100.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.